AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Immunogen (IMGN) shares surge on news of takeover by AbbVie (ABBV)
November 30, 2023 9:09 AM ESTAbbVie (NYSE: ABBV) announced Thursday that it will acquire Immunogen (NASDAQ: IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.
The transaction values ImmunoGen at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere... More
Sutro Biopharma (STRO) Trades Higher in Sympathy with Immunogen (IMGN)
November 30, 2023 7:45 AM ESTSutro Biopharma Inc. (NASDAQ: STRO) Trades Higher in Sympathy with Immunogen (NASDAQ: IMGN)
Earlier:
AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will... MoreImmunogen (IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (ABBV)
November 30, 2023 7:41 AM ESTImmunogen (NASDAQ: IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (NYSE: ABBV)
Earlier:
AbbVie Inc. (NYSE:... More